/STIM
STIM Stock - Neuronetics, Inc.
Healthcare|Medical - Diagnostics & ResearchNASDAQ
$1.40-1.06%
$0.01 (-1.06%) • Dec 19
63
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.92
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+471.4%upside
Target: $8.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for STIM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.39 – $1.41
TARGET (TP)$8.00
STOP LOSS$1.29
RISK/REWARD1:60.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.71
52W High$5.92
52W Low$1.25
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $74.89M | $71.35M | $65.21M | $55.31M | $49.24M |
| Gross Profit | $54.16M | $51.70M | $49.72M | $43.66M | $37.69M |
| Gross Margin | 72.3% | 72.5% | 76.3% | 78.9% | 76.5% |
| Operating Income | $-34,563,000 | $-30,554,000 | $-35,111,000 | $-27,564,000 | $-22,309,000 |
| Net Income | $-43,708,000 | $-30,189,000 | $-37,159,000 | $-31,193,000 | $-27,453,000 |
| Net Margin | -58.4% | -42.3% | -57.0% | -56.4% | -55.7% |
| EPS | $-1.38 | $-1.05 | $-1.38 | $-1.22 | $-1.46 |
Company Overview
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
0%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
0 Bullish0 Neutral/Bearish
Price Targets
No price targets available
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 13th 2024 | William Blair | Downgrade | Market Perform | - |
Earnings History & Surprises
STIMBeat Rate
44%
Last 18 quarters
Avg Surprise
-4.9%
EPS vs Estimate
Beats / Misses
8/9
1 met exactly
Latest EPS
$-0.13
Q4 2025
EPS Surprise History
Q1 24
+26.9%
$-0.19vs$-0.26
Q2 24
+18.2%
$-0.27vs$-0.33
Q3 24
-22.2%
$-0.33vs$-0.27
Q4 24
-26.1%
$-0.29vs$-0.23
Q1 25
-26.9%
$-0.33vs$-0.26
Q2 25
-61.5%
$-0.21vs$-0.13
Q3 25
-87.5%
$-0.15vs$-0.08
Q4 25
-8.3%
$-0.13vs$-0.12
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Mar 3, 2026 | $-0.12 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.12 | $-0.13 | -8.3% | ✗ MISS |
Q3 2025 | Aug 5, 2025 | $-0.08 | $-0.15 | -87.5% | ✗ MISS |
Q2 2025 | May 6, 2025 | $-0.13 | $-0.21 | -61.5% | ✗ MISS |
Q1 2025 | Mar 4, 2025 | $-0.26 | $-0.33 | -26.9% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.23 | $-0.29 | -26.1% | ✗ MISS |
Q3 2024 | Aug 12, 2024 | $-0.27 | $-0.33 | -22.2% | ✗ MISS |
Q2 2024 | May 7, 2024 | $-0.33 | $-0.27 | +18.2% | ✓ BEAT |
Q1 2024 | Mar 5, 2024 | $-0.26 | $-0.19 | +26.9% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.30 | $-0.33 | -10.0% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-0.34 | $-0.17 | +50.0% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.39 | $-0.38 | +2.6% | ✓ BEAT |
Q1 2023 | Mar 7, 2023 | $-0.43 | $-0.30 | +30.2% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-0.44 | $-0.28 | +36.4% | ✓ BEAT |
Q3 2022 | Aug 2, 2022 | $-0.43 | $-0.39 | +9.3% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.41 | $-0.41 | 0.0% | = MET |
Q1 2022 | Mar 8, 2022 | $-0.33 | $-0.29 | +12.1% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $-0.28 | $-0.31 | -10.7% | ✗ MISS |
Q3 2021 | Aug 3, 2021 | $-0.24 | $-0.29 | -20.8% | ✗ MISS |
Latest News
STIM stock has given up its prior loss. Neuronetics shares were trading lower after the company cut its FY2025 sales guidance below expectations.
➖ NeutralBenzinga•Nov 4, 2025, 03:11 PM
Neuronetics shares are trading lower after the company cut its FY2025 sales guidance below expectations.
📉 NegativeBenzinga•Nov 4, 2025, 12:29 PM
Neuronetics Lowers FY2025 Sales Guidance from $149.000M-$155.000M to $147.000M-$150.000M vs $151.030M Est
📉 NegativeBenzinga•Nov 4, 2025, 12:09 PM
Neuronetics Sees Q4 Sales $40.000M-$43.000M vs $43.057M Est
📉 NegativeBenzinga•Nov 4, 2025, 12:08 PM
Neuronetics Q3 EPS $(0.13) Misses $(0.10) Estimate, Sales $37.297M Miss $38.055M Estimate
📉 NegativeBenzinga•Nov 4, 2025, 12:06 PM
Neuronetics Announces Exclusive Three-Year Partnership To Become Sole Provider Of Transcranial Magnetic Stimulation Devices Across DNA's Locations
📈 PositiveBenzinga•Oct 30, 2025, 12:34 PM
New York Medicaid To Cover Neuronetics' TMS Therapy For Major Depressive Disorder Starting October 2025
📈 PositiveBenzinga•Sep 17, 2025, 12:41 PM
Frequently Asked Questions about STIM
What is STIM's current stock price?
Neuronetics, Inc. (STIM) is currently trading at $1.40 per share. The stock has moved -1.06% today.
What is the analyst price target for STIM?
The average analyst price target for STIM is $8.00, based on 1 analyst.
What sector is Neuronetics, Inc. in?
Neuronetics, Inc. operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the NASDAQ exchange.
What is STIM's market cap?
Neuronetics, Inc. has a market capitalization of $0.10 billion, making it a small-cap company.
Does STIM pay dividends?
No, Neuronetics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATLN
Atlantic International Corp.
$1.30
Mkt Cap: $0.1B
CATX
Perspective Therapeutics, Inc.
$2.75
Mkt Cap: $0.2B
CDXS
Codexis, Inc.
$1.66
Mkt Cap: $0.1B
GNFT
Genfit S.A.
$5.61
Mkt Cap: $0.3B
NYXH
Nyxoah S.A.
$4.85
Mkt Cap: $0.2B
OABI
OmniAb, Inc.
$2.09
Mkt Cap: $0.2B
OSUR
OraSure Technologies, Inc.
$2.39
Mkt Cap: $0.2B
PRE
Prenetics Global Limited
$17.48
Mkt Cap: $0.2B
PROF
Profound Medical Corp.
$7.63
Mkt Cap: $0.2B
SGMO
Sangamo Therapeutics, Inc.
$0.45
Mkt Cap: $0.2B
Explore stocks similar to STIM for comparison